Anavex Life Sciences Corp.
General ticker "AVXL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $781.2M (TTM average)
Anavex Life Sciences Corp. does not follow the US Stock Market performance with the rate: -13.6%.
Estimated limits based on current volatility of 3.8%: low 4.60$, high 4.97$
Factors to consider:
- Total employees count: 42 (+5.0%) as of 2024
- Top business risk factors: Operational and conduct risks, Product development risks, Third-party risks, Regulatory and compliance, Market competition
- Current price 14.0% below estimated low
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-09-30 to 2027-09-30
- 2025-09-30 to 2026-09-30 estimated range: [5.53$, 11.98$]
- 2026-09-30 to 2027-09-30 estimated range: [4.92$, 10.92$]
Financial Metrics affecting the AVXL estimates:
- Negative: with PPE of -16.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -5.30 <= 0.01
- Positive: Inventory ratio change, % of 0 <= 0.80
- Positive: Shareholder equity ratio, % of 91.38 > 64.29
- Positive: Investing cash flow per share per price, % of 0 > -0.63
- Negative: negative Net income
Short-term AVXL quotes
Long-term AVXL plot with estimates
Financial data
| YTD | 2023-09-30 | 2024-09-30 | 2025-09-30 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $55.76MM | $52.88MM | $51.41MM |
| Operating Income | $-55.76MM | $-52.88MM | $-51.41MM |
| Non-Operating Income | $8.26MM | $9.88MM | $5.03MM |
| R&D Expense | $43.72MM | $41.84MM | $37.59MM |
| Income(Loss) | $-47.50MM | $-43.00MM | $-46.38MM |
| Taxes | $0.01MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-47.51MM | $-43.00MM | $-46.38MM |
| Stockholders Equity | $141.85MM | $120.26MM | $94.87MM |
| Assets | $154.39MM | $135.57MM | $103.81MM |
| Operating Cash Flow | $-27.79MM | $-30.81MM | $-39.04MM |
| Financing Cash Flow | $29.65MM | $11.97MM | $9.43MM |
| Earnings Per Share** | $-0.60 | $-0.52 | $-0.54 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.